#1 Clinical Trials Search in Europe

Xanthum Gum

Recent clinical trials have been investigating the potential use of Xanthum Gum, a substance typically known for its use in food products, as a novel treatment for childhood asthma. This article explores the ongoing research into Xanthum Gum’s potential therapeutic applications, particularly focusing on its use in treating asthma-like symptoms in young children aged 1-5 years.

Table of Contents

What is XANTHUM GUM?

XANTHUM GUM is a medication that is currently being studied for its potential use in treating childhood asthma[1]. It is important to note that while the clinical trial information mentions XANTHUM GUM, the study actually focuses on azithromycin, which is an antibiotic. This discrepancy might be due to a data entry error or a placeholder name used in the trial documentation. For the purposes of this article, we will discuss the information as it relates to azithromycin, which is the actual drug being studied.

Azithromycin is typically used as an antibiotic to treat various bacterial infections. However, researchers are now exploring its potential benefits in treating asthma-like symptoms in young children[1].

Medical Condition: Childhood Asthma

The clinical trial is focused on treating childhood asthma, specifically in children aged 1-5 years who are hospitalized due to asthma-like symptoms[1]. Asthma is a chronic respiratory condition that affects the airways, causing them to narrow and produce excess mucus, making it difficult to breathe. In children, asthma can be particularly challenging to manage and can lead to hospitalization during severe episodes.

The study mentions several related terms for the condition being investigated[1]:

  • Asthma-like condition
  • Asthma/bronchitis
  • Exacerbation of asthma
  • Childhood asthma

Study Objectives

The main objective of this study is to investigate the effect of a three-day azithromycin treatment compared to a placebo in children aged 1-5 years who are hospitalized due to asthma-like symptoms[1]. The researchers aim to replicate the results of a previous study, which showed that azithromycin treatment significantly shortened the duration of asthmatic episodes.

Secondary objectives include[1]:

  1. Examining individual responses to treatment
  2. Potentially contributing to personalized treatment based on a child’s respiratory microbiome and/or immunological profile
  3. Increasing understanding of the influence of bacteria on asthma-like episodes in preschool children
  4. Developing evidence-based, improved treatments for childhood asthma

Eligibility Criteria

To participate in this study, children must meet specific inclusion criteria[1]:

  • Age between 12-71 months (1-5 years)
  • Previous episodes of asthma-like symptoms
  • Current medical treatment with short-acting beta-agonists (SABA) alone or in combination with inhaled corticosteroids (ICS) and possibly leukotriene receptor antagonists (LTRA)
  • Parents/guardians agree to admit the child and follow the trial procedure
  • Parents/guardians must be fluent in Danish

Children will be excluded from the study if they have[1]:

  • Known allergy to macrolide antibiotics
  • Impaired liver or kidney function
  • Neurological or psychiatric diseases
  • Congenital or acquired QT interval issues
  • Clinically relevant bradycardia, cardiac arrhythmia, or severe heart failure
  • Clinical signs of pneumonia
  • Use of medications that may interact with azithromycin

Study Endpoints

The primary endpoint of the study is the duration (in days) of the asthma-like episode from the start of randomization[1].

Secondary endpoints include[1]:

  1. Change in symptom score from day 1 after randomization to completion of the asthmatic episode
  2. Length of hospitalization
  3. Need for short-acting beta-agonists (SABA) during the asthma-like episode
  4. Need for oral corticosteroids (OCS) during the asthma-like episode
  5. Analysis based on the presence or absence of bacteria in the airways
  6. Percentage of days away from daycare and/or work for parents/guardians
  7. Assessment of health economic gain based on treatment costs and lost earnings for parents/guardians

Study Design

This clinical trial is designed as a randomized, controlled, double-blinded study[1]. This means that participants will be randomly assigned to either receive azithromycin or a placebo, and neither the participants nor the researchers will know which treatment each child is receiving during the study. This design helps to minimize bias and ensure the reliability of the results.

The study aims to explore a new indication for azithromycin, specifically for asthma exacerbation in hospitalized children aged 1-5 years. This makes it a Phase II therapeutic exploratory trial[1].

Aspect Details
Drug Name Xanthum Gum
Formulation Cream
Administration Route Oral
Target Condition Childhood asthma
Age Group 1-5 years
Trial Phase Therapeutic exploratory (Phase II)
Primary Objective Investigate effect on duration of asthmatic episodes
Secondary Objectives Examine individual response, understand bacterial influence on asthma-like episodes
Study Design Double-blind, randomized, controlled study

FAQ

  • What is Xanthum Gum and why is it being studied for asthma treatment? Xanthum Gum is a substance commonly used in food products, but researchers are now exploring its potential medical applications. It's being studied as a possible treatment for childhood asthma due to its unique properties that might help manage asthma symptoms.
  • What age group is being targeted in these clinical trials? The clinical trials are focusing on children aged 1-5 years who are hospitalized due to asthma-like symptoms.
  • How is Xanthum Gum being administered in the trials? While the exact administration method isn't specified in the trial data, Xanthum Gum is being tested as a cream formulation. The route of administration is listed as oral, suggesting it may be taken by mouth.
  • What are the main objectives of the clinical trials? The main objective is to investigate the effect of Xanthum Gum treatment compared to a placebo in shortening the duration of asthmatic episodes in hospitalized children aged 1-5 years.
  • Are there any known side effects or risks associated with Xanthum Gum treatment? The trial data doesn't mention specific side effects for Xanthum Gum. However, as with any medical treatment, researchers will be closely monitoring participants for any adverse reactions during the study.

Ongoing Clinical Trials on Xanthum Gum

  • Study on Azithromycin for Treating Hospitalized Children Aged 1-5 with Asthma Symptoms

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Asthma: A chronic lung condition that causes inflammation and narrowing of the airways, leading to breathing difficulties, coughing, and wheezing.
  • Placebo: A substance with no active medical effects, used as a control in testing new drugs to determine their effectiveness.
  • Randomized controlled trial: A type of scientific experiment where participants are randomly assigned to different treatment groups to compare the effects of various interventions.
  • SABA: Short-Acting Beta Agonists, a type of medication used for quick relief of asthma symptoms.
  • ICS: Inhaled Corticosteroids, a type of medication used to prevent and control asthma symptoms.
  • LTRA: Leukotriene Receptor Antagonists, a class of drugs used to manage asthma symptoms.
  • Exacerbation: A worsening of symptoms or an increase in the severity of a disease.
  • Microbiome: The collection of microorganisms, including bacteria, that live in or on the human body.
  • QT interval: A measurement on an electrocardiogram that represents the time it takes for the heart's electrical system to recharge between beats.

References

  1. http://clinicaltrials.eu/trial/study-on-azithromycin-for-treating-hospitalized-children-aged-1-5-with-asthma-symptoms/